What isnt there to love about this wee gem! Go you good thing! :D
Printable View
What isnt there to love about this wee gem! Go you good thing! :D
One thing not to love is how on earth does one add significantly more shares to their existing stake in decent volume without paying a sky high price ?
I managed to snag an extra 50,000 last week at 40 cents...wonder if anyone would like to donate another 50K to the hounds retirement fund at the same price, Percy are you reading this :D Suppose its best if I don't hold my breath lol
I am very surprised there have been no big sales.
I would have thought 50 cents would have attracted some one with 200,000 to 500,000 to sell.
I am too frightened to even think of selling any.?..
Last week you paid 40 cents.Up 35% in a week.You did well.
And the person who brought the 15,000 at 54 cents this morning is no fool....lol.
As you know mate based on some big guesses I have valued PAZ at just under 50 cents based on estimated 2020 earnings. The problem is I don't think anyone on here is investing based on 2020 earnings expectations, they're all licking their chops and thinking about 2021, 2022 and beyond earnings and a possible listing on the NZX down the track. That's where the fun really starts !
The Bear topped up a few @ $0.30 just before Covid struck and its caused The Bear a few sleepless nights when we went into Lockdown. I thought Gulp what have I done :eek2: what a difference a few weeks makes and I am sleeping quite well now :D
Nice 50,000 trades @.54-5 gone through today, well done , bejuses if we were listed on the NZX and going by the recent history of AFT we would be in for a rerating sometime.
With all of the current C R in N Z going on at present Im betting that PAZ will announce one some time shortly--- when the ducks are quacking----feed them !!
From USX newsletter.
Healthy Future: A Pharmazen Story
Given the journey that global markets have gone through over recent months, it is heartening to see those special securities that have remained strong over this time. PharmaZen has been the most notable of these, smashing $100m market capitalisation to become one of the top performing companies listed on the USX. However this spectacular achievement has not been an overnight success.
Based in Christchurch, PharmaZen Ltd (trading as Waitaki Biosciences) is a biotech company focusing on the development, manufacture and B2B marketing of specialised nutritional ingredients. The company’s products targets, both the human and companion animal dietary supplement industries, with over 90% of product exported to foreign markets.
PAZ’s first trade on the USX was in February 2005, at a price of $0.04, and since then has traded below $0.10 for most of its history. That is, until recently.
In early 2018, USX facilitated for PharmaZen a capital raise of c. $4.1m to provide the funds required to accelerate the completion of several major expansion projects, including:
Installation of the largest batch freeze dryer in Australasia (increasing capacity by 75%)
Deployment of its specialised solvent extraction facility
Commissioning of an additional 1,000 sqm of production facilities
GMP (Good Manufacturing Practice) certification, ensuring approval to manufacture active pharmaceutical ingredients by Medsafe
Licensing and patents for further consumer ready products
High levels of demand for its products saw the company fully utilising its new production capacity, and revenue soared to $12.6m in 2018 from $7.3m the previous year. Additionally, PharmaZen strengthened its management team by bringing in a new COO and CTO, who further drove the future aspirations of the company.
In March this year, just as Covid-19 was dealing blows to global markets, PharmaZen released its 2019 financial report which only served to boost investor confidence further. The company increased its YOY revenue by 38%, and its EBITDA by 98%, demonstrating the continued global appetite for its products and the improving margin as staff had time to get used to the new plant.
Since then, PharmaZen has traded as high as $0.55, more than double its pre-lockdown price and 10x the price of its first trade. This rapid growth has seen the company surpass $100m market capitalisation, to become one of the top performing companies listed on the USX.